Increased vision impairment reports linked to semaglutide: analysis of FDA adverse event data

Increased vision impairment reports linked to semaglutide: analysis of FDA adverse event data

Abstract Background Semaglutide, a GLP-1 receptor agonist widely prescribed for type 2 diabetes and obesity, has recently raised concerns about its ocular safety. This study aimed to investigate the association between semaglutide use and vision impairment using data from the FDA Adverse Event Repor...

Full description

Saved in:
Bibliographic Details
Main Authors: Marine Massy, Stefanie Marti, Helly Hammer, Robert Hoepner
Format: Article
Language:English
Published: BMC 2025-04-01
Series:BMC Medicine
Subjects:
Semaglutide
Vision impairment
Diabetes
Obesity
Online Access:https://doi.org/10.1186/s12916-025-04031-z
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12916-025-04031-z

Similar Items